

VIII) Literaturverzeichnis:

Antos, C. L., McKinsey, T. A., Dreitz, M., Hollingsworth, L. M., Zhang, C.-L., Schreiber, K., Rindt, H., Gorczynski, R. J., and Olson, E. N. (2003). Dose-dependent Blockade to Cardiomyocyte Hypertrophy by Histone Deacetylase Inhibitors. *J Biol Chem* 278, 28930-28937.

Antos, C. L., McKinsey, T. A., Frey, N., Kutschke, W., McAnally, J., Shelton, J. M., Richardson, J. A., Hill, J. A., and Olson, E. N. (2002). Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. *Proc Natl Acad Sci U S A* 99, 907-912.

Badorff, C., Ruetten, H., Mueller, S., Stahmer, M., Gehring, D., Jung, F., Ihling, C., Zeiher, A. M., and Dimmeler, S. (2002). Fas receptor signaling inhibits glycogen synthase kinase 3 beta and induces cardiac hypertrophy following pressure overload. *J Clin Invest* 109, 373-381.

Barnes, P. J., and Karin, M. (1997). Nuclear factor- κ B - a pivotal transcription factor in chronic inflammatory diseases. *N Engl J Med* 336, 1066-1071.

Bellenger, N. G., Swinburn, J. M., Rajappan, K., Lahiri, A., Senior, R., and Pennell, D. J. (2002). Cardiac remodelling in the era of aggressive medical therapy: does it still exist? *Int J Cardiol* 83, 217-225.

Bergmann, M., Hart, L., Lindsay, M., Barnes, P. J., and Newton, R. (1998). IkappaBalpha degradation and nuclear factor-kappaB DNA binding are insufficient for interleukin-1beta and tumor necrosis factor-alpha-induced kappaB-dependent transcription. Requirement for an additional activation pathway. *J Biol Chem* 273, 6607-6610.

Bergmann, M. W., Loser, P., Dietz, R., and von Harsdorf, R. (2001). Effect of NF-kappa B Inhibition on TNF-alpha-induced apoptosis and downstream pathways in cardiomyocytes. *J Mol Cell Cardiol* 33, 1223-1232.

Bergmann, M. W., Rechner, C., Freund, C., Baurand, A., El Jamali, A., and Dietz, R. (2004a). Statins inhibit reoxygenation-induced cardiomyocyte apoptosis: role for glycogen synthase kinase 3[beta] and transcription factor [beta]-catenin. *Journal of Molecular and Cellular Cardiology* 37, 681-690.

Bergmann, M. W., Staples, K. J., Barnes, P. J., and Newton, R. (2004b). Nuclear factor-kappaB does not mediate the inhibitory effects of dexamethasone on granulocyte-macrophage colony-stimulating factor expression. *Immunology* 111, 430-434.

Bergmann, M. W., Staples, K. J., Smith, S. J., Barnes, P. J., and Newton, R. (2004c). Glucocorticoid Inhibition of Granulocyte Macrophage-Colony-Stimulating Factor from T cells Is Independent of Control by Nuclear Factor- κ B and Conserved Lymphokine Element 0. *Am J Respir Cell Mol Biol* 30, 555-563.

Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., Skene, A. M., and the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators (2004). Intensive

versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. *N Engl J Med* 350, 1495-1504.

Chan, A. W., Bhatt, D. L., Chew, D. P., Quinn, M. J., Moliterno, D. J., Topol, E. J., and Ellis, S. G. (2002). Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. *Circulation* 105, 691-696.

Clerk, A., Harrison, J. G., Long, C. S., and Sugden, P. H. (1999). Pro-inflammatory cytokines stimulate mitogen-activated protein kinase subfamilies, increase phosphorylation of c-Jun and ATF2 and upregulate c-Jun protein in neonatal rat ventricular myocytes. *J Mol Cell Cardiol* 31, 2087-2099.

Communal, C., Singh, K., Sawyer, D. B., and Colucci, W. S. (1999). Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis : role of a pertussis toxin-sensitive G protein. *Circulation* 100, 2210-2212.

Condorelli, G., Drusco, A., Stassi, G., Bellacosa, A., Roncarati, R., Iaccarino, G., Russo, M. A., Gu, Y., Dalton, N., Chung, C., *et al.* (2002). Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. *Proc Natl Acad Sci U S A* 99, 12333-12338.

Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M., and Hemmings, B. A. (1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. *Nature* 378, 785-789.

Ding, B., Price, R. L., Borg, T. K., Weinberg, E. O., Halloran, P. F., and Lorell, B. H. (1999). Pressure Overload Induces Severe Hypertrophy in Mice Treated With Cyclosporine, an Inhibitor of Calcineurin. *Circ Res* 84, 729-734.

El Jamali, A., Freund, C., Rechner, C., Scheidereit, C., Dietz, R., and Bergmann, M. W. (2004). Reoxygenation after severe hypoxia induces cardiomyocyte hypertrophy in vitro: activation of CREB downstream of GSK3 β . *FASEB J* 18, 1096-1098.

Esposito, G., Rapacciuolo, A., Naga Prasad, S. V., Takaoka, H., Thomas, S. A., Koch, W. J., and Rockman, H. A. (2002). Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. *Circulation* 105, 85-92.

Fentzke, R. C., Korcarz, C. E., Lang, R. M., Lin, H., and Leiden, J. M. (1998). Dilated Cardiomyopathy in Transgenic Mice Expressing a Dominant- Negative CREB Transcription Factor in the Heart. *J Clin Invest* 101, 2415-2426.

Group, H. P. S. (2002). MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet* 360, 7-22.

Hardt, S. E., and Sadoshima, J. (2002). Glycogen synthase kinase-3 β : a novel regulator of cardiac hypertrophy and development. *Circ Res* 90, 1055-1063.

- Hatada, E. N., Krappmann, D., and Scheidereit, C. (2000). NF-kappaB and the innate immune response. *Curr Opin Immunol* 12, 52-58.
- Haunstetter, A., and Izumo, S. (2000). Toward antiapoptosis as a new treatment modality. *Circ Res* 86, 371-376.
- Hilfiker-Kleiner, D., Hilfiker, A., Fuchs, M., Kaminski, K., Schaefer, A., Schieffer, B., Hillmer, A., Schmiedl, A., Ding, Z., Podewski, E., *et al.* (2004). Signal Transducer and Activator of Transcription 3 Is Required for Myocardial Capillary Growth, Control of Interstitial Matrix Deposition, and Heart Protection From Ischemic Injury. *Circ Res* 95, 187-195.
- Hirota, H., Chen, J., Betz, U. A., Rajewsky, K., Gu, Y., Ross, J., Jr, Muller, W., and Chien, K. R. (1999). Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. *Cell* 97, 189-198.
- Hjalmarson, A., Goldstein, S., Fagerberg, B., Wedel, H., Waagstein, F., Kjekshus, J., Wikstrand, J., El Allaf, D., Vitovec, J., Aldershvile, J., *et al.* (2000). Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. *JAMA* 283, 1295-1302.
- Irwin, M. W., Mak, S., Mann, D. L., Qu, R., Penninger, J. M., Yan, A., Dawood, F., Wen, W. H., Shou, Z., and Liu, P. (1999). Tissue expression and immunolocalization of tumor necrosis factor- α in postinfarction dysfunctional myocardium. *Circulation* 99, 1492-1498.
- Ito, K., Barnes, P. J., and Adcock, I. M. (2000). Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1 β -induced histone H4 acetylation on lysines 8 and 12. *Mol Cell Biol* 20, 6891-6903.
- Kang, P. M., and Izumo, S. (2000). Apoptosis and heart failure: A critical review of the literature. *Circ Res* 86, 1107-1113.
- Kucharczak, J., Simmons, M. J., Fan, Y., and Gelinas, C. (2003). To be, or not to be: NF-kappaB is the answer--role of Rel/NF-kappaB in the regulation of apoptosis. *Oncogene* 22, 8961-8982.
- Kureishi, Y., Luo, Z., Shiojima, I., Bialik, A., Fulton, D., Lefer, D. J., Sessa, W. C., and Walsh, K. (2000). The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. *Nat Med* 6, 1004-1010.
- Lansbury, P. T., Jr. (2004). Back to the future: the 'old-fashioned' way to new medications for neurodegeneration. *Nat Med* 10 *Suppl*, S51-57.
- Liu, Z. P., Nakagawa, O., Nakagawa, M., Yanagisawa, H., Passier, R., Richardson, J. A., Srivastava, D., and Olson, E. N. (2001). CHAMP, a novel cardiac-specific helicase regulated by MEF2C. *Dev Biol* 234, 497-509.

Matsui, T., Li, L., Wu, J. C., Cook, S. A., Nagoshi, T., Picard, M. H., Liao, R., and Rosenzweig, A. (2002). Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. *J Biol Chem* 277, 22896-22901.

Minamino, T., Gaussin, V., DeMayo, F. J., and Schneider, M. D. (2001). Inducible gene targeting in postnatal myocardium by cardiac-specific expression of a hormone-activated Cre fusion protein. *Circ Res* 88, 587-592.

Misra, A., Haudek, S. B., Knuefermann, P., Vallejo, J. G., Chen, Z. J., Michael, L. H., Sivasubramanian, N., Olson, E. N., Entman, M. L., and Mann, D. L. (2003). Nuclear Factor- κ B Protects the Adult Cardiac Myocyte Against Ischemia-Induced Apoptosis in a Murine Model of Acute Myocardial Infarction. *Circulation* 108, 3075-3078.

Molkentin, J. D. (2000). Calcineurin and beyond: cardiac hypertrophic signaling. *Circ Res* 87, 731-738.

Molkentin, J. D., Lu, J. R., Antos, C. L., Markham, B., Richardson, J., Robbins, J., Grant, S. R., and Olson, E. N. (1998). A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. *Cell* 93, 215-228.

Nadal-Ginard, B., Kajstura, J., Leri, A., and Anversa, P. (2003). Myocyte Death, Growth, and Regeneration in Cardiac Hypertrophy and Failure. *Circ Res* 92, 139-150.

Nakamura, T., Sano, M., Songyang, Z., and Schneider, M. D. (2003). A Wnt- and beta-catenin-dependent pathway for mammalian cardiac myogenesis. *Proc Natl Acad Sci U S A* 100, 5834-5839.

Newton, R. (2000). Molecular mechanisms of glucocorticoid action: what is important? *Thorax* 55, 603-613.

Newton, R., Hart, L. A., Stevens, D. A., Bergmann, M., Donnelly, L. E., Adcock, I. M., and Barnes, P. J. (1998). Effect of dexamethasone on interleukin-1beta-(IL-1beta)-induced nuclear factor-kappaB (NF-kappaB) and kappaB-dependent transcription in epithelial cells. *Eur J Biochem* 254, 81-89.

Newton, R., Staples, K. J., Hart, L., Barnes, P. J., and Bergmann, M. W. (2001). GM-CSF expression in pulmonary epithelial cells is regulated negatively by posttranscriptional mechanisms. *Biochem Biophys Res Commun* 287, 249-253.

Pfeffer, M. A., McMurray, J. J. V., Velazquez, E. J., Rouleau, J.-L., Kober, L., Maggioni, A. P., Solomon, S. D., Swedberg, K., Van de Werf, F., White, H., *et al.* (2003). Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. *N Engl J Med* 349, 1893-1906.

Poole-Wilson, P. A., Swedberg, K., Cleland, J. G. F., Di Lenarda, A., Hanrath, P., Komajda, M., Lubsen, J., Lutiger, B., Metra, M., and Remme, W. J. (2003). Comparison of carvedilol and

metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. *The Lancet* 362, 7-13.

Purcell, N. H., Tang, G., Yu, C., Mercurio, F., DiDonato, J. A., and Lin, A. (2001). Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. *Proc Natl Acad Sci U S A* 98, 6668-6673.

Serruys, P. W. J. C., de Feyter, P., Macaya, C., Kokott, N., Puel, J., Vrolix, M., Branzi, A., Bertolami, M. C., Jackson, G., Strauss, B., *et al.* (2002). Fluvastatin for Prevention of Cardiac Events Following Successful First Percutaneous Coronary Intervention: A Randomized Controlled Trial. *JAMA* 287, 3215-3222.

Staples, K. J., Bergmann, M., Tomita, K., Houslay, M. D., McPhee, I., Barnes, P. J., Giembycz, M. A., and Newton, R. (2001). Adenosine 3',5'-cyclic monophosphate (cAMP)-dependent inhibition of IL-5 from human T lymphocytes is not mediated by the cAMP-dependent protein kinase A. *J Immunol* 167, 2074-2080.

Staples, K. J., Bergmann, M. W., Barnes, P. J., and Newton, R. (2003). Evidence for post-transcriptional regulation of interleukin-5 by dexamethasone. *Immunology* 109, 527-535.

Vaughan, C. J., Gotto, A. M., Jr., and Basson, C. T. (2000). The evolving role of statins in the management of atherosclerosis. *J Am Coll Cardiol* 35, 1-10.

Walter, D. H., Fichtlscherer, S., Britten, M. B., Auch-Schwelk, W., Schachinger, V., and Zeiher, A. M. (2002). Benefits of immediate initiation of statin therapy following successful coronary stent implantation in patients with stable and unstable angina pectoris and Q-wave acute myocardial infarction. *The American Journal of Cardiology* 89, 1-6.

Wang, C. Y., Cusack, J. C., Jr, Liu, R., and Baldwin, A. S., Jr (1999). Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. *Nat Med* 5, 412-417.

Yamamoto, K., Ohki, R., Lee, R. T., Ikeda, U., and Shimada, K. (2001). Peroxisome Proliferator-Activated Receptor γ Activators Inhibit Cardiac Hypertrophy in Cardiac Myocytes. *Circulation* 104, 1670-1675.

Yang, G., Meguro, T., Hong, C., Asai, K., Takagi, G., Karoor, V. L., Sadoshima, J., Vatner, D. E., Bishop, S. P., and Vatner, S. F. (2001). Cyclosporine reduces left ventricular mass with chronic aortic banding in mice, which could be due to apoptosis and fibrosis. *J Mol Cell Cardiol* 33, 1505-1514.

Yaoita, H., Sakabe, A., Maehara, K., and Maruyama, Y. (2002). Different effects of carvedilol, metoprolol, and propranolol on left ventricular remodeling after coronary stenosis or after permanent coronary occlusion in rats. *Circulation* 105, 975-980.

Yeung, A. C., and Tsao, P. (2002). Statin Therapy: Beyond Cholesterol Lowering and Antiinflammatory Effects. *Circulation* 105, 2937-2938.

Zhang, C. L., McKinsey, T. A., Chang, S., Antos, C. L., Hill, J. A., and Olson, E. N. (2002). Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. *Cell* *110*, 479-488.